Research programme: cellular and protein based therapeutics - Celyad

Drug Profile

Research programme: cellular and protein based therapeutics - Celyad

Alternative Names: C3BS GQR 4; C3BS-GQR-1; C3BS-GQR-2; C3BS-GQR-3; C3BS-PQR-1

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cardio3 BioSciences
  • Developer Celyad
  • Class Proteins; Stem cell therapies
  • Mechanism of Action Cell differentiation stimulants; Cell replacements; Stem cell stimulants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Myocardial infarction
  • Research Congenital heart defects
  • No development reported Heart failure

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Heart-failure in Belgium
  • 05 May 2015 Cardio3 BioSciences is now called Celyad
  • 07 Oct 2014 Early research in Congenital heart disorders in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top